 |
|
Systemic Adjuvant Therapy for Patients With High-Risk Melanoma
Kenneth Y. Tsai, MD, PhD
Arch Dermatol. 2007;143(6):779-782.
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
Commentary on: Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma
Verma S, Quirt I, McCready D, Bak K, Charette M, Iscoe N
Cancer. 2006;106:1431-1442
Question: What is the evidence that systemic adjuvant therapy is of benefit in patients with high-risk resected melanoma? In their study, Verma et al include patients with thick melanomas (at least 4.0 mm in thickness), Clark level V tumor, primary melanoma with in-transit metastases, primary melanoma with clinically apparent lymph node involvement or a positive sentinel lymph node biopsy result, resected lymph node disease with no known primary site, and current American Joint Committee on Cancer (AJCC) 2002 stage IIB, IIC, and III disease.
Data Sources: The MEDLINE, CANCERLIT, EMBASE, and Cochrane Library databases were searched for articles published between 1980 and 2004, as were American Society of Clinical Oncology proceedings (1996-2004) detailing ongoing . . . [Full Text of this Article] Comment
AUTHOR INFORMATION
Department of Dermatology, Harvard Medical School, Boston, Mass
RELATED ARTICLES
Cloud Over Sentinel Node Biopsy: Unlikely Survival Benefit in Melanoma
Urbà González
Arch Dermatol. 2007;143(6):775-776.
EXTRACT
| FULL TEXT
The Current Status of Evaluation and Treatment of High-Risk Cutaneous Melanoma: Therapeutic Breakthroughs Remain Elusive
Matthew H. Kanzler
Arch Dermatol. 2007;143(6):785-787.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
The Current Status of Evaluation and Treatment of High-Risk Cutaneous Melanoma: Therapeutic Breakthroughs Remain Elusive
Kanzler
Arch Dermatol 2007;143:785-787.
FULL TEXT
|
